CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $61.35M, above the global median of $16.24M
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.63%Below 5Y avg (1.44%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
44.1%Sustainable
Last Ex-Dividend
Jul 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.16BCNY617.93M · vs all stocks (USD)
Trailing P/E
44.41xvs Biotechnology peers
Revenue (TTM)
373.31MCNY55.44M · vs all stocks (USD)
Profit Margin
23.88%vs Biotechnology peers
Beta
0.2290xvs all stocks
52-Week Change
-25.49%vs all stocks
Market Capitalization
4.16BCNY617.93M · vs all stocks (USD)
Enterprise Value
3.25BCNY482.27M · vs all stocks (USD)
Trailing P/E
44.41xvs Biotechnology peers
Forward P/E
29.61xvs Biotechnology peers
Price to Sales (TTM)
10.66xvs Biotechnology peers
Price to Book (MRQ)
2.14xvs Biotechnology peers
Enterprise to Revenue
8.70xvs Biotechnology peers
Enterprise to EBITDA
33.27xvs Biotechnology peers
Gross Margin
45.41%vs Biotechnology peers
Profit Margin
23.88%vs Biotechnology peers
Operating Margin
11.18%vs Biotechnology peers
Return on Assets (TTM)
1.99%vs Biotechnology peers
Return on Equity (TTM)
4.86%vs Biotechnology peers
Revenue (TTM)
373.31MCNY55.44M · vs all stocks (USD)
Revenue per Share (TTM)
1.43CNYUpdated Aug 20, 2026Quarterly Revenue Growth
9.50%vs Biotechnology peers
Gross Profit (TTM)
187.73MCNY27.88M · vs all stocks (USD)
EBITDA (TTM)
87.52MCNY13.00M · vs all stocks (USD)
Net Income (TTM)
89.14MCNY13.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-26.50%vs Biotechnology peers
Operating Cash Flow (TTM)
131.12MCNY19.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
413.06MCNY61.35M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.63%vs all stocks
5-Year Average Dividend Yield
1.44%vs all stocks
Payout Ratio
44.12%vs Biotechnology peers
Revenue
365.92MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
177.46MCNYFY2025 · Dec 31, 2025Gross Profit
188.46MCNYFY2025 · Dec 31, 2025Operating Income
84.40MCNY12.54M · vs all stocks (USD)
Pre-tax Income
103.83MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.31MCNYFY2025 · Dec 31, 2025Net Income
94.52MCNYFY2025 · Dec 31, 2025EBIT
103.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.39MCNYFY2025 · Dec 31, 2025Research & Development
35.71MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
19.87MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
144.43KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
262.55MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
262.55MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
94.52MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
42.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
-253.96MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
99.65MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
94.52MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-18.55MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.42MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-296.12MCNYFY2025 · Dec 31, 2025Purchase of Investments
-896.88MCNYFY2025 · Dec 31, 2025Sale of Investments
1.10BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-88.97MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-39.52MCNYFY2025 · Dec 31, 2025Other Financing Charges
-889.27KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.41MCNYFY2025 · Dec 31, 2025Shares Outstanding
263.50MSharesUpdated Aug 20, 2026Float Shares
141.42MSharesUpdated Aug 20, 2026% Held by Insiders
47.31%vs all stocks
% Held by Institutions
8.85%vs all stocks
Total Cash (MRQ)
734.84MCNY109.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.79CNYUpdated Aug 20, 2026Total Debt (MRQ)
3.25MCNY482.13K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0018xvs Biotechnology peers
Current Ratio (MRQ)
7.73xvs Biotechnology peers
Book Value per Share (MRQ)
7.05CNYUpdated Aug 20, 2026Total Assets
2.02BCNY299.85M · vs all stocks (USD)
Total Current Assets
977.34MCNYFY2025 · Dec 31, 2025Total Liabilities
176.08MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
48.48MCNYFY2025 · Dec 31, 2025Total Current Liabilities
127.60MCNYFY2025 · Dec 31, 2025Cash
98.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
99.70MCNYFY2025 · Dec 31, 2025Other Short-term Investments
110.21MCNYFY2025 · Dec 31, 2025Accounts Receivable
69.06MCNYFY2025 · Dec 31, 2025Inventory
46.47MCNYFY2025 · Dec 31, 2025Accounts Payable
88.08MCNYFY2025 · Dec 31, 2025Short-term Debt
785.07KCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.16MCNYFY2025 · Dec 31, 2025Long-term Debt
2.80MCNYFY2025 · Dec 31, 2025Common Stock (Book)
263.50MCNYFY2025 · Dec 31, 2025Retained Earnings
414.82MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.84BCNY273.70M · vs all stocks (USD)
52-Week Low
13.02CNYUpdated Aug 20, 202652-Week High
27.08CNYUpdated Aug 20, 202652-Week Change
-25.49%vs all stocks
Beta
0.2290xvs all stocks
50-Day MA
14.70CNYUpdated Aug 20, 2026200-Day MA
17.12CNYUpdated Aug 20, 2026Avg 10-Day Volume
5.31MSharesUpdated Aug 20, 2026Avg 30-Day Volume
4.55MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.3400CNYUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $61.35M, above the global median of $16.24MNotable
Levered free cash flow (USD): 61,347,994.38Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
China Zhenhua Group Science & Technology Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Doushen Beijing Education Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Mueller Industries Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity